Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CorMedix Inc. (CRMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.3600-0.1300 (-3.72%)
At close: 04:00PM EDT
3.3400 -0.02 (-0.60%)
After hours: 05:21PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4900
Open3.5200
Bid3.2700 x 1800
Ask3.4100 x 1800
Day's Range3.2800 - 3.5700
52 Week Range2.8700 - 8.3800
Volume309,778
Avg. Volume370,937
Market Cap127.97M
Beta (5Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)-0.7310
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
  • GlobeNewswire

    CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

    Conference Call Scheduled for Today at 4:30 p.m. Eastern TimeBERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2022 and provided an update on recent business events. Recent Corporate Highlights: CorMedix announced on March 28 t

  • GlobeNewswire

    CorMedix Inc. Announces Leadership Updates and Operational Changes

    BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its leadership team and changes regarding its international operations: Joe Todisco, Chief Executive Officer of CorMedix, officially joined the organization on Tuesday May 10th. Liz Hurlburt, EVP of Clinical Operati

  • GlobeNewswire

    CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

    BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the first quarter ended March 31, 2022, after the market close on Thursday, May 12, 2022, and will host a corporate update conference call at 4:30pm Eastern Time. Thursday, May 12th @ 4:

Advertisement
Advertisement